About 180 Life Sciences Corp. 180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases ...

180 Life Sciences Corp. is pleased to provide a corporate update covering several key initiatives. "We believe that this acquisition is a pivotal moment for the Company," said Blair Jordan ...

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the ...

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the ...

180 Life Sciences is exploring the use of synthetic cannabidiol (CBD) analogs as a treatment strategy for inflammation and pain, and conducting clinical research focused on repurposing anti-tumor ...

180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules AccesswireFri, Dec. 27, 2024 ...

180 Life Sciences is led by Dr. James Woody who previously served as the founding CEO of OncoMed Pharmaceuticals, as well as President and General Manager of Roche Bioscience.

180 Life Sciences Trading Up 2.4% Shares of NASDAQ:ATNF opened at $0.91 on Friday. The company has a 50 day moving average of $0.99 and a 200-day moving average of $1.15. The firm has a market cap ...

Home page Seeking Alpha - Power to Investors Search for Symbols, analysts, keywords Log in 180 Life Sciences Corp. - Corporate Updates Oct. 03, 2024 8:30 AM ET180 Life Sciences Corp. (ATNF) ...

About 180 Life Sciences Corp. is a publicly-traded company that focuses on developing new technologies across multiple sectors. With its current portfolio of inflammation focused intellectual property ...